Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering-Reference-Cited by-同舟云学术

Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering

Published:2017-11 Issue: Volume:11 Page:S91-S97
ISSN:1871-4021
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
language:en
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Author:

Fleischmann Holger,Göke Rüdiger,Bramlage Peter

Publisher

Elsevier BV

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group;Turner;JAMA,1999

2. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes;Baxter;Acta Diabetol,2008

3. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1);Riddle;Diabetes Care,2013

4. Nocturnal glucose control with an artificial pancreas at a diabetes camp;Phillip;N Engl J Med,2013

5. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet (London, England). 1999; 354: 617-21.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning;IRAN J BASIC MED SCI;2020

2. Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study;Diabetes Therapy;2019-01-17